Modality
Program #
Program
Indication
Preclinical development
Phase 1
Phase 2
Phase 3 and commercial
Moderna rights
Prophylactic Vaccines
mRNA-1172

RSV vaccine

Progress: 100%
Progress: 25%
mRNA-1777

RSV vaccine

Progress: 100%
Progress: 99%

Merck to pay milestones and royalties

mRNA-1647

CMV vaccine

Progress: 100%
Progress: 90%

Worldwide

mRNA-1653

hMPV+PIV3 vaccine

Phase 1b
(pediatrics)
Phase 1
(adults)
Progress: 100%
Progress: 99%

Worldwide

mRNA-1440

Influenza H10N8 vaccine

Progress: 100%
Progress: 99%

Worldwide
Advancing subject to funding

mRNA-1851

Influenza H7N9 vaccine

Progress: 100%
Progress: 99%

Worldwide
Advancing subject to funding

mRNA-1893

Zika vaccine

Progress: 100%
Progress: 25%

Worldwide
BARDA funded

mRNA-1388

Chikungunya vaccine

Progress: 100%
Progress: 99%

Worldwide
Advancing subject to funding

Cancer Vaccines
mRNA-4157

Personalized cancer vaccine (PCV)

Progress: 100%
Progress: 100%
Progress: 10%
NCI-4650

Personalized cancer vaccine (PCV)

Progress: 100%
Progress: 50%

50-50 global profit sharing with Merck

mRNA-5671

KRAS vaccine
CRC, NSCLC, pancreatic cancer

Progress: 100%
Progress: 25%

50-50 global profit sharing with Merck

Intratumoral Immuno-Oncology
mRNA-2416

OX40L
Solid tumors/lymphoma
Advanced ovarian carcinoma (Ph 2 cohort)

Solid tumors/lymphoma
Ovarian
Progress: 100%
Progress: 99%

Worldwide

mRNA-2752

OX40L+IL23+IL36γ (Triplet)
Solid tumors/lymphoma

Progress: 100%
Progress: 40%

Worldwide

MEDI1191

IL12
Solid tumors

Progress: 100%
Progress: 25%

50-50 U.S. profit sharing; AZ to pay royalties on ex-U.S. sales

Localized Regenerative Therapeutics
AZD8601

VEGF-A
Myocardial ischemia

Progress: 100%
Progress: 100%
Progress: 50%

AZ to pay milestones and royalties

Systemic Secreted Therapeutics
mRNA-1944

Antibody against Chikungunya virus

Progress: 100%
Progress: 75%

Worldwide

AZD7970

Relaxin
Heart failure

Progress: 60%

50-50 U.S. profit sharing; AZ to pay royalities on ex-U.S. sales

mRNA-3630

α-GAL
Fabry disease

Progress: 60%

Worldwide

Systemic Intracellular Therapeutics
mRNA-3704

MUT
Methylmalonic acidemia, MMA

Progress: 99%

Worldwide

mRNA-3927

PCCA+PCCB
Propionic acidemia, PA

Progress: 65%

Worldwide

mRNA-3283

PAH
Phenylketonuria, PKU

Progress: 65%

Worldwide

mRNA-3745

G6Pase
Glycogen Storage Disorder
Type 1a, GSD1a

Progress: 65%

Worldwide

*Life -cycle to mRNA-1893
Abbreviations: AZ, AstraZeneca; α-GAL, alpha galaxtosidase; CMV, cytomegalovirus; CRC, colorectal cancer; G6Pase, glucose 6-phosphatase; hMPV, human metapneumovirus; IL12, interleukin 12; IL23, interleukin 23; IL36γ, interleukin 36 gamma; MUT, methylmalonyl-CoA mutase; NSCLC, non-small cell lung cancer; PAH, phenylalanine hydroxylase; PCCA/PCCB, propionyl-CoA carboxylase subunit A/B; PCV, personalized cancer vaccine; PIV3, human parainfluenza 3; RSV, respiratory syncytial virus; VEGF-A, vascular endothelial growth factor A; VZV, varicella zoster virus.